AstraZeneca PLC (AZN) Announced Q1 2026 Earnings on April 29, 2026, Reporting "Total revenue grew 8% in the quarter".

AstraZeneca PLC reported that "Total revenue grew 8% in the quarter" driven by robust demand for innovative medicines. "Core operating profit grew by 12%" and "Core EPS grew by 5% to $2.58" in the first quarter.

Performance varied across segments, with "Oncology total revenues grew 16% in the first quarter to $6.8 billion" and "Rare Disease delivered total revenue of $2.4 billion in quarter 1". Conversely, "Biopharmaceuticals total revenue declined by 2% to $5.8 billion" in the quarter.

Management highlighted continued momentum, securing 14 approvals in major regions since the Q4 2025 results.

The company announced results from 4 positive Phase III programs, including new molecular entities tozorakimab and efzimfotase alfa. "Core R&D expenses increased by 8%" in the first quarter as the company continued to invest in its pipeline and "transformative technologies, including cell therapies and T cell engagers".The company reiterated its full year guidance, noting that total revenue is "anticipated to increase by mid- to high single-digit percentage" and core EPS is "anticipated to increase by low double-digit percentage" at constant exchange rates.

Notable pipeline progress included positive primary analysis data from the Phase III EMERALD-3 trial for Imfinzi in combination with Imjudo.

Management also noted preparations for upcoming product launches, including the anticipated "quarter 2" regulatory decision for baxdrostat.